# Johnson & Johnson CDR (CAD Hedged) (JNJ.TO) fundamentals

Data as of 2026-11-04. TSX, Canada. Sector: Healthcare / Pharmaceuticals. Price C$33.86, market value C$838.5 billion.

## Valuation
- **P/E (trailing): 40.8×** (5-yr avg 24.8×, 3-yr avg 24.8×). Johnson & Johnson CDR (CAD Hedged) trades at 40.8× trailing earnings, well above its own five-year average of 24.8×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 8.4×**. Each dollar of revenue is priced at 8.4×.
- **Price / book: 10.6×**. The shares trade at 10.6× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 32.3×**. Enterprise value is 32.3× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 2.3%** (5-yr avg 2.9%). Free cash flow equals 2.3% of the market value, in line with its five-year average of 2.9%.
- **Earnings yield: 2.5%**. The inverse of the P/E: 2.5% of the price is earned each year.

## Profitability
- **Gross margin: 67.6%**. Johnson & Johnson CDR (CAD Hedged) keeps 67.6% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 25.7%**. 25.7% of revenue is left after running the business, an exceptional level.
- **Net margin: 28.5%**. 28.5% of each dollar of sales reaches the bottom line.
- **Return on equity: 32.9%**. 32.9% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 21.2%**. Return on all capital, debt included, is 21.2%: comfortably above what that capital costs.
- **Return on assets: 8.1%**. Each dollar of assets produces 8.1% of profit.

## Growth
- **Revenue growth (1 yr): 6.0%** (3-yr 5.6%/yr). Revenue grew 6.0% over the last year.
- **EPS growth (1 yr): 90.5%** (3-yr 17.9%/yr). Earnings per share rose 90.5%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 4.0%/yr**. Free cash flow has compounded at 4.0% a year over three years, lagging earnings: check whether profits are turning into cash.

## Financial health
- **Debt to equity: 0.59**. Debt is 0.59 times equity, moderate leverage.
- **Net debt / EBITDA: 1.0×**. It would take 1.0 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 25.9×**. Operating profit covers interest 25.9× over, a safe margin.
- **Current ratio: 1.03** (quick 0.77). Current assets cover the next year's liabilities 1.03 times.
- **Altman Z-score: 5.89**. A Z-score of 5.89 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Johnson & Johnson CDR (CAD Hedged) does not currently pay a dividend, but it returned 0.9% of its market value through buybacks over the last year.

## Price and momentum
- **From 52-week high: -5.8%** (29.4% above the low). Trading 6% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 61**. An RSI of 61 is neutral.
- **Beta (1 yr): 0.06** (volatility 21%). Beta of 0.06 against the S&P/TSX Composite: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=JNJ.TO · Page: https://foliofundamentals.com/stocks/jnj.to

Not investment advice.